Full Text View
Tabular View
No Study Results Posted
Related Studies
Resistance to Vitamin D or Parathyroid Hormone
This study is currently recruiting participants.
Study NCT00001242   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: July 23, 2009   History of Changes

November 3, 1999
July 23, 2009
September 1989
 
 
HIV disease progression (new or recurrent AIDS defining illness) or death as a first event.
Complete list of historical versions of study NCT00001242 on ClinicalTrials.gov Archive Site
 
CD4+ cell count changes, Plasma HIV RNA load changes, HIV disease progression alone, Survival, Treatment discontinuations, HIV risk behavior, Productivity analysis, Health care utilization. Quality of life, Nutritional status.
 
Resistance to Vitamin D or Parathyroid Hormone
Studies of States With Resistance to Vitamin D and Parathyroid Hormone

Patients with confirmed or suspected conditions with a resistance to vitamin D or parathyroid hormone (PTH) will be admitted for diagnosis and treatment, and inclusion in other studies pertaining to similar conditions.

This study will provide information about problems relating to calcium in the blood, urine, and bones. Patients in this study will undergo a general evaluation / check-up to give researchers an idea of each person's condition or disease. Patients will receive treatment based on their diagnosis and asked to provide specimen samples for further research studies.

Patients with confirmed or suspected states with resistance to vitamin D or parathyroid hormone (PTH) will be admitted for diagnosis and treatment and for inclusion in other protocols. These states include hypocalcemia, rickets, osteomalacia, pseudohypoparathyroidism. Resistance to a factor is manifested by deficient bioeffect despite high levels of the factor in blood. Patients will be tested with multiple indices of mineral metabolism to establish the diagnosis and examine the spectrum of the underlying disorder. The principal therapies will be combinations of calcium, phosphate, and a vitamin D analog. Selected patients will have localization and surgery to remove a tumor that causes renal wasting of phosphate. Patients will be considered for entry into other research protocols.

 
Observational
 
  • Hypocalcemia
  • Osteomalacia
  • Pseudohypoparathyroidism
  • Pseudopseudohypoparathyroidism
  • Rickets
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
99999999
 
 
  • INCLUSION CRITERIA:

Patients of any age or sex with vitamin D resistance, rickets, osteomalacia, pseudohypoparathyroidism, pseudo-pseudohypoparathyroidism, or suspicion of these or related disorders based upon the appropriateness of their problem to ongoing investigations.

Current investigations are focused primarily upon subjects with target tissue resistance to 1,25-dihydroxyvitamin D, pseudohypoparathyroidism, and pseudo-pseudohypoparathyroidism.

Both
1 Year and older
No
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010
United States
 
NCT00001242
 
890173, 89-DK-0173
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 
 
National Institutes of Health Clinical Center (CC)
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP